Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib before radical prostatectomy for localized prostate cancer
ACTRN12618000354280Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ribociclib in prostate cancer (PCa) (2 arms), sponsored by University of Sydney. Primary endpoint: Tumor cell proliferation reduction. Started Nov 2018; status: completed.
02
Drugs
ribociclib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12618000354280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000354280.